CC BY

Repetitive transcranial magnetic stimulation for treatment of limb spasticity following multiple sclerosis: a systematic review and meta-analysis

Dongyun Su¹*⁰, Anzi Wang²*⁰, Meirong Zhu¹⁰, Fei Yang¹⁰, Wei Li¹⁰, Bo Ma¹⁰, Min Liu¹⁰, Zongqi Li¹⁰, Bo Wang¹⁰, Huanyi Tu¹⁰, and Bo Ning⁰

¹Department of Neurology, The First People's Hospital of Longquanyi District Chengdu, Longquanyi District, Chengdu, China ²Department of Hematology, The Third People's Hospital of Chengdu, Qingyang District, Chengdu, China

Abstract

Pilot trials have suggested that repetitive transcranial magnetic stimulation (rTMS) may reduce limb spasticity in multiple sclerosis (MS). We carried out the current meta-analysis to synthesize currently available evidence regarding such correlation. Up to November 2022, five international electronic databases (Cochrane CENTRAL, PubMed, Embase, Web of Science, and CINAHL) and four Chinese electronic databases (CBM, CNKI, WanFang Data, and VIP) were systematically searched to identify randomized trials comparing active rTMS and sham stimulation in patients with MS-related spasticity. Two reviewers independently selected studies and extracted data on study design, quality, clinical outcomes, and time points measured. The primary outcome was clinical spasticity relief after intervention. Secondary outcomes included spasticity at the follow-up visit 2 weeks later and post-treatment fatigue. Of 831 titles found, we included 8 studies (181 participants) in the quantitative analysis. Pooled analyses showed that rTMS therapy was associated with significant spasticity relief in the early post-intervention period [standardized mean differences (SMD): -0.67; 95%CI: -1.12 to -0.21], but there was insufficient evidence for rTMS in reducing spasticity at the follow-up visit 2 weeks later (SMD: -0.17; 95%CI: -0.52 to 0.17) and fatigue (SMD: -0.26; 95%CI: -0.84 to 0.31). This evidence supports the recommendations to treat MS-related spasticity with rTMS, but underlines the need for further large randomized trials.

Key words: Efficacy; Meta-analysis; Multiple sclerosis; Spasticity; Repetitive transcranial magnetic stimulation

Introduction

Multiple sclerosis (MS) is a chronic neurological and inflammatory disorder of the central nervous system (CNS) that predominantly occurs in young adults and affects approximately 2.5 million people worldwide (1-3). MS occurs in early life and has only a modest negative effect on longevity, so that problems of rapidly progressing physical disability, activity restriction, social isolation, and psychosocial adjustment progress over time and place a significant burden on affected individuals, informal caregivers, and the health care system (4,5). Spasticity is a common disabling physical symptom in patients with MS, with reports of affecting 60-90% of MS survivors (6-8). It may affect the trunk musculature, resulting in restricted joint mobility, poor postural control, and loss of dexterity. impacting caregiver burden and guality of life (QoL) (9). Furthermore, spasticity has a direct correlation with disease progression and other condition-related impairments such as pain, fatigue, and cognitive deficits, which also impact patient function (10).

Pharmacological and non-pharmacological interventions are the mainstay of spasticity management for MS patients. The former includes antispasmodic medications such as baclofen, benzodiazepines, dantrolene sodium, and tizanidine, while the latter includes physical, surgical, and instrumental approaches. However, current medical treatments are partially effective and can be associated with various systemic side effects (drowsiness, muscle weakness, and cognitive impairment) (11,12). Neurosurgical procedures are invasive and considered only for severe spasticity following the failure of pharmacological agents (13). Therefore, new approaches for MS treatment are needed.

Repetitive transcranial magnetic stimulation (rTMS) is a neurostimulation and neuromodulation technique that

Correspondence: Bo Ning: <544854201@qq.com>

*These authors contributed equally to this article.

Received February 17, 2023 | Accepted April 15, 2023

has been widely applied to treat several symptoms in people living with MS (pwMS) (14). Due to its neuroplasticity properties and effects on motor cortex excitability at both short- and long-lasting intervals, rTMS can modulate motor corticospinal output, thereby remodeling local and distant excitability with a tangible effect on limb spasticity (15–17). Current data regarding the relationship between application of rTMS over the primary motor cortex and symptoms of limb spasticity in pwMS are conflicting. Some authors have reported reduction of spasticity associated with high-frequency rTMS (HF-rTMS) and intermittent theta-burts (iTBS) treatment, but these findings have not been consistently replicated (18-25). A recent meta-analysis (26), which identified 8 original controlled studies that directly compared active rTMS and sham stimulation totaling 161 MS patients, failed to observe significant anti-spastic effects of active rTMS. However, retrospective checks confirmed that one eligible trial (24) had been omitted in the process of literature screening. Given that the omission of relevant data probably introduced bias and affected the reliability of relevant results, no formal recommendation could be made for this indication. Furthermore, no prior metaanalyses have focused exclusively on patients diagnosed of MS-related spasticity to date. The aim of this work was to evaluate the intervention effects of rTMS in pwMS with spasticity through a systematic review and meta-analysis of evidence from randomized controlled trials.

Material and Methods

Data sources and search strategy

We searched multiple international cross-disciplinary electronic databases (PubMed, Embase, Web of Science, Cochrane CENTRAL, and CINAHL) and Chinese electronic databases (Chinese Bio-medicine Database [CBM], Wan-Fang Data, Chinese National Knowledge Infrastructure [CNKI], and China Science and Technology Journal Database databases [VIP]) from inception of each database until November 2022. The selected keywords were obtained by review of primary search results and controlled vocabularies - Medical Subject Headings (MeSH) in PubMed and Cochrane library (Supplementary Table S1 for details). Searches were limited to completed human studies, published in English or Chinese, in any year. Bibliographies of journal articles, reviews, and editorials were manually searched to identify potentially eligible studies. We also reviewed abstracts from major international meetings in the field to locate any unpublished studies. This work was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (27) and was registered in PROSPERO (International Prospective Register of Systematic Reviews; reference number: CRD420223 52922).

Study selection

After removing the duplicates, the 2 principal investigators (D.Y.S. and A.Z.W.) independently screened the title and abstract of retrieved studies according to prespecified inclusion/exclusion criteria. In case of uncertainty, the full texts of the selected studies were reviewed. Any disagreement on the process of selection was resolved by consensus.

Studies were included if they met the following criteria: i) participants had a confirmed diagnosis of MS based on validated criteria and suffered from limb spasticity as measured by the Modified Ashworth Scale (MAS) scored greater than or equal to one point; ii) randomized controlled trials (RCTs) comparing real rTMS with sham control. Trials performing less than 10 intervention sessions were excluded. The frequency of stimulation, target area, intensity, and duration were not limited; iii) at least one clinical outcome was reported for spasticity or fatigue, irrespective of whether it was a primary or secondary outcome. We excluded non-randomized observational studies, reviews, comments, and trials that did not provide sufficient data. If multiple investigations were based on the same population data, the articles with comprehensive information would be included.

Data extraction and quality assessment

The articles that met the inclusion criteria were obtained in electronic format. Two investigators (D.Y.S. and A.Z.W.) independently extracted data from eligible papers on standardized Microsoft Excel spreadsheets, based on the Cochrane data extraction tool. Data extraction forms were used to collect pertinent information about study type, the first author, year of publication, country, study inclusion and exclusion criteria, number of patients in each treatment arm, type of MS, number of pulses per session, intensity of stimulation, risk of bias, details on rTMS and comparator groups, outcomes, and time points measured. We attempted to contact the authors of primary studies to supplement incomplete information. Assessment of the risk of bias in included studies was performed according to the Risk of Bias Assessment Tool from the Cochrane Handbook (28), and any discrepancy or uncertainty was resolved by consensus among authors.

Definition of outcomes

The primary outcome was defined as short-term (within 1 week after the last session) rTMS effect as measured by mean score changes in clinical spasticity symptoms from baseline to end-point. If data were available for more than one time-point in the article, we gave preference to the time-point closest to the last session. If a study used multiple spasticity measures, preference was given to the measure reported by the majority of the included studies. If a study reported two or more outcome measures, and none of the other included studies used any of them, preference was given to the measure listed as primary in this study.

Pre-specified secondary analyses included the following: i) efficacy at short-term follow-up, as measured by mean score change in spasticity symptoms from baseline to 2 weeks after the end of the stimulation course. The selection priority of spasticity scales was the same as for the primary outcome; ii) fatigue symptoms, as measured by mean score change on fatigue severity scales from baseline to just after the last session.

Data synthesis and analysis

To pool data from different continuous scales and ordinal scales with no standard cut-off point, we calculated standardized mean differences (SMD) and 95% confidence intervals (CIs) for the same outcomes. Betweenstudy heterogeneity was evaluated using the Cochran Q test and I^2 value. When $I^2 > 40\%$ and P value <0.1, pooled risk estimates were calculated using the Der-Simonian and Laird random-effects models, adjusting for within-study and between-study variation. The fixedeffects (Mantel-Haenszel) models were used to obtain more precise estimates where there was no evidence of significant heterogeneity (29). Subgroup analyses with regard to the primary outcome were performed based on type of MS (relapsing remitting vs secondary progressive), type of intervention (HF-rTMS vs iTBS), sex ratio (female/ male, >1 vs ≤ 1), and whether it was combined with conventional rehabilitation to explore the effect of these indicators on spasticity symptom in pwMS. Sensitivity analyses were performed by sequentially removing individual studies to assess whether any specific report could influence the overall results. In addition to funnel plots, the Egger test (30) was performed for publication bias assessment. All statistical analyses were performed using Review Manager 5.3.3 (Cochrane, UK) and Stata 12 (USA) software, with a P value of less than 0.05 considered statistically significant.

Results

Search results and characteristics of included studies

The process of study selection is shown in Figure 1. Our search identified 831 potentially eligible citations (Supplementary Table S2). After removing the duplicates and review of titles and abstracts, 699 citations were excluded and 23 were ultimately retained for further evaluation. Fifteen studies were excluded for the following reasons: not rTMS (n=2), not MS-related spasticity (n=5), review articles (n=1), not sham control (n=2), or lack of pertinent data (n=5).

The design of 8 studies included (18–25) in this metaanalysis are summarized in Table 1. The studies were published from 1996 to 2019 and were conducted in 6 countries. Among 181 patients diagnosed with MS-related



Figure 1. Flow diagram of literature search and study selection. RCT: randomized controlled trial; MS: multiple sclerosis; rTMS: repetitive transcranial magnetic stimulation.

spasticity in 8 randomized trials, 106 patients were assigned to HF-rTMS or iTBS, and 75 patients were assigned to sham stimulation, with a mean age of 50 years and a sex ratio of 0.7 (male/female 75/106). Four studies involved patients with relapsing remitting (RR) MS (19,20,22,23), one included patients with secondary progressive (SP) MS (21), one recruited both RR and SP MS (18), and the remaining two studies did not specify the type of MS (24,25). In addition, there were 5 studies that concerned conventional limb rehabilitation (such as physical therapy or exercise therapy). For those studies that more than one active group, we considered each arm as one study in the quantitative analysis.

Outcomes

Eight trials totaling 181 patients provided data sufficient for meta-analysis on the short-term spasticity outcome after treatment. There was significant heterogeneity among the studies (P=0.04, l^2 =50%), thereby random-effects models were used for analysis. The overall pooled effect size calculated using the DerSimonian-Laird method showed a significant benefit of rTMS therapy in reducing limb spasticity within a week of the last session (SMD: -0.67; 95%CI: -1.12 to -0.21; P=0.004; Figure 2). As for spasticity reduction at the follow-up visit 2 weeks later, there was no statistical difference between active rTMS group and sham stimulation group (SMD: -0.17; 95%CI: -0.52 to 0.17; P=0.32; l^2 =35%; Figure 3A). In terms of fatigue outcome, data were pooled and calculated using fixed-effects models. No statistical

disease T b France SP/RR iTBS once 8) working	Treatment group	Comparator group	size		/+00				
France SP/RR iTBS once working		-	(T/C), n		(ieiiiaie, %)		pulses		
	e daily for 13 consecutive 3 days + standardized rehabilitation	Sham iTBS + standardized rehabilitation	9/8	51.6 ± 10.6	47.06%	80% AMT	600	VAS	Improvement of spasticity was greater in iTBS group than in sham iTBS group (P=0.026)
Italy RR 5 Hz r consecu	rTMS once daily for 5 utive days for 2 weeks	Sham rTMS	12/7	41.4±6.1	73.68%	100% RMT	006	MAS	rTMS may improve spasticity in MS
Spain RR iTBS onc ses	ce daily for 10 treatment ssions (two weeks)	Sham iTBS	10/7	49.8 ± 9.8	58.82%	80% AMT	600	MAS	iTBS did not produce any significant clinical effect on spasticity
Russia SP 20 Hz consecuti	rTMS once daily for 5 tive days for 2 weeks + physical therapy	Sham rTMS + physical therapy	12/5	41.7 ± 17.7	61.76%	80% AMT	1600	MAS, SESS, NAS, MFIS	MAS was significantly reduced after the stimulation course in the HF-rTMS group
Russia SP ITBS onco	e daily for 5 consecutive or 2 weeks + physical therapy	Sham iTBS + physical therapy	12/5	46.7 ± 7.8	55.88%	80% MSP	1200	MAS, SESS, NAS, MFIS	MAS was significantly reduced after the stimulation course in the iTBS group
ltaly RR iTBS onci di	e daily for 5 consecutive lays for 2 weeks	Sham iTBS	10/10	44.3 ± 12.5	65%	80% AMT	600	MAS	Patients receiving iTBS showed a significant reduction of MAS scores
Italy RR iTBS onc days fo	e daily for 5 consecutive or 2 weeks + exercise therapy	Sham iTBS + exercise therapy	10/10	38.4 ± 11.2	35%	80% AMT	600	MAS, MSSS- 88, FSS	A combination of iTBS and ET ameliorated spasticity
Denmark NA 25 Hz i consecutiv activity	rTMS twice daily for 7 ve days + daily physical / and physical therapy	Sham rTMS + daily physical activity and physical therapy	21/17	44 (26–67)	68.42%	AN	AN	Clinical spasticity score	rTMS had an antispastic effect in MS
Turkey NA 5 Hz r] session physical th	TMS once daily for 10 ins lasting 2 weeks + therapy and rehabilitation program	Sham rTMS + physical therapy and rehabilitation program	10/6	49.93 ± 12.27	50%	110% RMT	006	MAS	Active rTMS reduced spasticity in MS patients compared to control group

Table 1. Characteristics of included randomized controlled trials.

	rTN	IS gro	up	sha	m gro	up	:	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Random, 95% CI	IV. Random, 95% CI
Boutière 2016	-28.8	19.6	9	-10.6	17.3	8	10.7%	-0.93 [-1.95, 0.09]	
Centonze 2007	-2.02	1.7	12	0.02	1.69	7	10.7%	-1.15 [-2.17, -0.13]	
Dieguez-Varela 2019	-0.54	0.98	10	-1.98	1.73	7	10.4%	1.03 [-0.02, 2.07]	
Korzhova 2019	-1	0.55	12	-0.2	0.42	5	9.0%	-1.46 [-2.65, -0.28]	
Korzhova 2019	-1.5	1	12	-0.2	0.42	5	9.1%	-1.40 [-2.57, -0.22]	
Mori 2010	-1.76	2.98	10	-0.6	1.83	10	12.2%	-0.45 [-1.34, 0.44]	
Mori 2011	-0.8	0.4	10	-0.4	0.6	10	11.9%	-0.75 [-1.67, 0.16]	
Nielsen 1996	-3.5	6.2	21	-1.2	7.4	17	15.7%	-0.33 [-0.98, 0.31]	
Şan 2019	-1.1	1.45	10	0.16	0.82	6	10.0%	-0.94 [-2.02, 0.14]	
Total (95% CI)			106			75	100.0%	-0.67 [-1.12, -0.21]	•
Heterogeneity: Tau ² =	0.24; Ch	i ² = 15	.93, df	= 8 (P =	0.04)	12 = 50	196	-	
Test for overall effect:	Z = 2.86	(P = 0	.004)						Favours [experimental] Favours [control]

Figure 2. Forest plot for short-term relief of spasticity symptoms. CI: confidence interval; df: degrees of freedom; IV: inverse variance; SD: standard deviation; Std: standardized; rTMS: repetitive transcranial magnetic stimulation. See Table 1 for reference numbers.

Α									
	rTM	S gro	цþ	sha	m gro	qu		Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV. Fixed, 95% Cl
Boutière 2016	-31.4	18.9	9	-23.4	18.3	8	12.6%	-0.41 [-1.37, 0.56]	
Centonze 2007	-0.4	2.13	12	0.02	1.89	7	13.5%	-0.20 [-1.13, 0.74]	
Dieguez-Varela 2019	-0.88	1.23	10	-2.26	1.65	7	11.1%	0.93 [-0.10, 1.96]	
Korzhova 2019	-1.37	0.84	12	-0.37	1.49	5	9.7%	-0.90 [-2.00, 0.20]	
Korzhova 2019	-1	168	12	-0.37	1.49	5	10.8%	-0.00 [-1.05, 1.04]	
Mori 2010	-2.72	3.66	10	0.3	2.65	10	13.6%	-0.91 [-1.84, 0.03]	
Nielsen 1996	-0.8	8.3	21	-1.2	8.1	17	28.7%	0.05 [-0.59, 0.69]	
Total (95% CI)			86			59	100.0%	-0.17 [-0.52, 0.17]	•
Heterogeneity: Chi2 = 9	9.24. df =	6 (P =	= 0.16)	² = 35	%				
Test for overall effect:	Z = 0.98	(P = 0	.32)						-4 -2 U Z 4
									ravours (experimental) ravours (control)
в									
	rTM	S groi	qu	sha	m gro	ир		Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV. Fixed. 95% CI
Korzhova 2019	-8.2	7.7	12	-7.1	12	5	30.0%	-0.12 [-1.16, 0.93]	
Korzhova 2019	-5.6	13	12	-7.1	12	5	30.0%	0.11 [-0.93, 1.16]	_ _ _
Mori 2011	-7.9	4.4	10	-5	4	10	39.9%	-0.66 [-1.57, 0.25]	
Total (95% CI)			34			20	100.0%	-0.26 [-0.84, 0.31]	•
Heterogeneity: Chi2 =	1.31, df :	= 2 (P	= 0.52	; ² = 09	16			-	
Test for overall effect:	Z = 0.91	(P = (0.36)						-4 -2 U 2 4
	_ 0.01	1. 1							Favours [experimental] Favours [control]

Figure 3. Forest plot of secondary outcomes. **A**, Spasticity at the follow-up visit 2 weeks later. **B**, Post-treatment fatigue. CI: confidence interval; df: degrees of freedom; IV: inverse variance; SD: standard deviation; Std: standardized; rTMS: repetitive transcranial magnetic stimulation. See Table 1 for reference numbers.

difference was observed between these two groups (3 trials, n=54; SMD: -0.26; 95%Cl: -0.84 to 0.31; P=0.36; $I^2=0\%$; Figure 3B).

Subgroup analyses

When stratified by type of MS, rTMS therapy significantly reduced limb spasticity among SP MS (SMD: -1.43; 95%CI: -2.26 to -0.60) but not RR MS (SMD: -0.35; 95%CI: -1.22 to 0.53); however, the difference between the two subgroups was not significant (P for interaction=0.08) (Figure 4). In a subgroup analysis by type of intervention, there was no difference between iTBS (SMD: -0.49; 95%CI: -1.25 to 0.27) and HF-rTMS (SMD: -0.81: 95%CI: -1.33 to -0.30) concerning the spasticity outcome (P for interaction=0.49). Similarly, in a subgroup analysis based on sex, no significant subgroup difference was observed (P for interaction=0.54). In addition, a subgroup analysis was also performed according to whether treatment was combined with conventional rehabilitation. A larger effect size was observed when rTMS application was combined with rehabilitation training (SMD: -0.80; 95%CI: -1.18 to -0.41 vs SMD: -0.20; 95%

CI: -1.40 to 1.00); however, the difference between the two subgroups was not significant (P for interaction=0.35).

Sensitivity analyses

Sensitivity analyses were performed to examine the robustness of our results. In order to identify whether any research had a disproportionate influence on the summary treatment effect, we removed studies one at a time. Deleting individual studies did not significantly alter the results. In the study by Şan et al. (25), the evaluation parameters of short-term effects were assessed one week after the last session rather than immediately after applying rTMS. Sensitivity analysis by excluding this study achieved a consistent result (Supplementary Figure S1).

Quality assessment and publication bias

The tool for assessing risk of bias recommended by the Cochrane Collaboration was used to assess the quality of the included RCTs (Supplementary Figure S2). The overall bias was low in 3 studies (19,22,24) and medium in 5 studies (18,20,21,23,25). The inverted funnel plot for motor outcome was visually asymmetric (Figure 5). Egger regression test indicated no publication bias (P=0.319), but Begg rank correlation test indicated possible publication bias (P=0.029) (Supplementary Figure S3). The trim-and-fill method was used to recalculate our pooled risk estimate. The analysis showed that the imputed effect size was -0.71 (95%CI: -1.19 to -0.22), which was consistent with our original risk estimate. No missing trials were imputed in the contour-enhanced funnel plot (Supplementary Figure S4).

Discussion

In the current study, we systematically reviewed the literature to assess the efficacy of rTMS in MS patients with spasticity. The meta-analysis found that rTMS significantly improved spasticity in the early post-intervention period, although there was significant heterogeneity probably due to sample size or disease duration. Moreover, our results suggested no significant benefit of rTMS compared with sham control for spasticity reduction during the follow-up period, as well as no significant reduction in fatigue at the post-treatment evaluation.

Even though spasticity does not have exclusively negative aspects for the patient, since a paretic limb may allow the patient to continue to walk, stand, and move, there is a great variety of dramatic short- and long-term negative consequences on daily life activities (31–33). MS can have a fluctuating and often progressive course, making spasticity management more challenging. The relationship of rTMS and the two major symptoms of fatigue and spasticity in MS patients has also been the subject of an earlier meta-analysis, in which a nonsignificant association between rTMS treatment and early

A	rTMS group	sham gro	up		Std. Mean Difference	Std. Mean Difference	В	rTMS group	sham gr	oup	Std. Mean Difference	Std. Mean Difference	
141 RR	Mean SD Tota	Mean SD	Total	Weight	IV. Random, 95% CI	IV. Random, 95% Cl	1.9.1 HE_rTMS	Mean SD Tota	Mean S	D Total Weig	ht IV. Random, 95% CI	IV. Random. 95% CI	
Centonze 2007	-2.02 1.7 1	2 0.02 1.69	7	16.9%	-1.15 [-2.17, -0.13]		Centonze 2007	-2.02 1.7 1	2 0.02 1.6	9 7 10.7	% -1.15 [-2.170.13]		
Dieguez-Varela 2019	-0.54 0.98 1	0 -1.98 1.73	7	16.6%	1.03 [-0.02, 2.07]		Korzhova 2019	-1 0.55 1	-0.2 0.4	2 5 9.0	% -1.46 [-2.65, -0.28]		
Mori 2010	-1.76 2.98 1	0 -0.6 1.83	10	18.3%	-0.45 [-1.34, 0.44]		Nielsen 1996	-3.5 6.2 2	-1.2 7.	4 17 15.7	% -0.33 [-0.98, 0.31]		
Mori 2011	-0.8 0.4 1	0 -0.4 0.6	10	18.1%	-0.75 [-1.67, 0.16]		Şan 2019	-1.1 1.45 1	0.16 0.8	2 6 10.0	% -0.94 [-2.02, 0.14]		
Subtotal (95% CI)	4	2	34	69.8%	-0.35 [-1.22, 0.53]		Subtotal (95% CI)	5	5	35 45.5	-0.81 [-1.33, -0.30]	-	
Test for overall effect: 2	0.55; Chi ² = 9.83, df Z = 0.78 (P = 0.44)	= 3 (P = 0.02);	ls = 69%	0			Heterogeneity: Tau ² = Test for overall effect:	0.06; Chi ² = 3.72, df Z = 3.08 (P = 0.002)	= 3 (P = 0.29); I ^z = 19%			
1.4.2 SP							1.9.2 iTBS						
Korzhova 2019	-1 0.55 1	2 -0.2 0.42	5	15.0%	-1.46 [-2.65, -0.28]		Boutière 2016	-28.8 19.6	-10.6 17.	3 8 10.7	% -0.93 [-1.95, 0.09]		
Korzhova 2019	-1.5 1 1	2 -0.2 0.42	5	15.2%	-1.40 [-2.57, -0.22]		Dieguez-Varela 2019	-0.54 0.98 1	-1.98 1.7	3 7 10.4	% 1.03 [-0.02, 2.07]	-	
Subtotal (95% CI)	2 00 01 7 0 01 1	4	10	30.2%	-1.43 [-2.26, -0.60]		Korzhova 2019	-1.5 1 1	2 -0.2 0.4	2 5 9.1	% -1.40 [-2.57, -0.22]		
Heterogeneity: Tau* = 1	0.00; Chi* = 0.01, df	= 1 (P = 0.94);	1= 0%				Mon 2010	-1.76 2.98 1	-0.6 1.8	3 10 12.2	% -0.45 [-1.34, 0.44]		
rescior overall effect.	2 = 3.30 (P = 0.0000	9					Subtotal (95% CI)	-0.0 0.4 1	/ -0.4 0.	40 54 5	-0.75 [-1.07, 0.16]	-	
Total (95% CI)	6	6	44	100.0%	-0.67 [-1.39, 0.04]	•	Heterogeneity: Tau ² =	0.48 Chi ² = 11.46 d	f = 4 (P = 0.0)	2): 1 ² = 65%			
Heterogeneity: Tau ² =	0.52; Chi ² = 14.46, d	f = 5 (P = 0.01)	; l ² = 65 ⁴	%	· · · -		Test for overall effect:	Z = 1.27 (P = 0.20)		-,			
Test for overall effect: 2	Z = 1.85 (P = 0.06)					-4 -2 U 2 4 Favours [experimental] Favours [control]							
Test for subaroup diffe	rences: Chi ² = 3.11.	df = 1 (P = 0.0)	 l² = 67 	7.8%		rateau (experimental)	Total (95% CI)	10		75 100.0	-0.67 [-1.12, -0.21]	· · · · · · · · · · · · · · · · · · ·	
							Heterogeneity: Tau ² =	0.24; Chi ² = 15.93, d	f = 8 (P = 0.0-	4); l ² = 50%	-	-4 -2 0 2 4	
							Test for subgroup diffs	Z = 2.86 (P = 0.004)	df = 1 /P = 0	390 - SI (01		Favours [experimental] Favours [control]	
-								161068. GIII - 0.40.	ui = 117 = 0.5	431.1 = 0.8			
С	rTMS group	ebam ar	un.		Std. Mean Difference	Std. Mean Difference	D	rTMS group	sham ar	oup	Std. Mean Difference	Std Mean Difference	
C Study or Subgroup	rTMS group Mean SD Tot	sham gro al Mean SD	up Total	Weight	Std. Mean Difference	Std. Mean Difference	D Study or Subgroup	rTMS group Mean SD Tota	sham gr I Mean Si	roup D Total Weig	Std. Mean Difference ht IV. Random, 95% Cl	Std. Mean Difference IV. Random, 95% Cl	
C Study or Subgroup 1.7.1 F/M>1	rTMS group Mean SD Tot	sham gro al Mean SD	oup Total	Weight	Std. Mean Difference IV. Random, 95% Cl	Std. Mean Difference IV. Random. 95% Cl	D Study or Subgroup 1.5.1 with rehabilitati	rTMS group Mean SD Tota on therapy	sham gr I Mean Si	roup D Total Weig	Std. Mean Difference ht IV. Random. 95% CI	Std. Mean Difference IV. Random, 95% Cl	
C Study or Subgroup 1.7.1 F/M>1 Centonze 2007	rTMS group Mean SD Tot	sham gro al Mean SD 2 0.02 1.69	Total	Weight	Std. Mean Difference IV. Random, 95% Cl -1.15 [-2.17, -0.13]	Std. Mean Difference IV. Random, 95% Cl	D Study or Subgroup 1.5.1 with rehabilitati Boutière 2016	rTMS group Mean SD Tota on therapy -28.8 19.6	sham gr <u>I Mean S</u> -10.6 17.	roup D Total Weig 3 8 10.7	Std. Mean Difference ht IV. Random, 95% Cl % -0.93 [-1.95, 0.09]	Std. Mean Difference IV. Random. 95% Cl	
C <u>Study or Subgroup</u> 1.7.1 F/M>1 Centonze 2007 Dieguez-Varela 2019	rTMS group Mean SD Tot -2.02 1.7 1 -0.54 0.98 1	sham gro al Mean SD 2 0.02 1.69 0 -1.98 1.73	Total	Weight 10.7% 10.4%	Std. Mean Difference IV. Random, 95% CI -1.15 [-2.17, -0.13] 1.03 [-0.02, 2.07]	Std. Mean Difference	D <u>Study or Subgroup</u> 1.5.1 with rehabilitati Boutière 2016 Korzhova 2019	rTMS group Mean SD Tota on therapy -28.8 19.6 1 -1 0.55 1	sham gr I Mean Si 9 -10.6 17. 2 -0.2 0.4	roup D Total Weig 3 8 10.7 2 5 9.0	Std. Mean Difference IV. Random. 95% Cl % -0.93 [-1.95, 0.09] % -1.46 [-2.65, -0.28]	Std. Mean Difference IV. Random, 95% Cl	
C <u>Study or Subgroup</u> 1.7.1 F/M>1 Centonze 2007 Dieguez-Varela 2019 Korzhova 2019	rTMS group Mean SD Tot -2.02 1.7 1 -0.54 0.98 1 -1 0.55 1	sham gro al Mean SD 2 0.02 1.69 0 -1.98 1.73 2 -0.2 0.42	Total 7 7 5	Weight 10.7% 10.4% 9.0%	Std. Mean Difference <u>IV. Random. 95% Cl</u> -1.15 [-2.17, -0.13] 1.03 [-0.02, 2.07] -1.46 [-2.65, -0.28]	Std. Mean Difference IV. Random. 95% Cl	D Study or Subgroup 1.5.1 with rehabilitati Boutière 2016 Korzhova 2019 Korzhova 2019	rTMS group <u>Mean SD Tota</u> on therapy -28.8 19.6 -1 0.55 11 -1.5 1 11	sham gr I Mean S 9 -10.6 17. 2 -0.2 0.4 2 -0.2 0.4	roup D Total Weig 3 8 10.7 2 5 9.0 2 5 9.1	Std. Mean Difference ht IV. Random. 95% Cl % -0.93 [-1.95, 0.09] % -1.46 [-2.65, -0.28] % -1.40 [-2.57, -0.22]	Std. Mean Difference IV. Random. 95% Cl	
C <u>Study or Subgroup</u> 1.7.1 F/M>1 Centonze 2007 Dieguez-Varela 2019 Korzhova 2019 Korzhova 2019	rTMS group Mean SD Tot -2.02 1.7 1 -0.54 0.98 1 -1 0.55 1 -1.5 1 1	sham gro al Mean SD 2 0.02 1.69 0 -1.98 1.73 2 -0.2 0.42 2 -0.2 0.42	Total 7 7 5 5	Weight 10.7% 10.4% 9.0% 9.1%	Std. Mean Difference IV. Random, 95% CI -1.15 [-2.17, -0.13] 1.03 [-0.02, 2.07] -1.46 [-2.65, -0.28] -1.40 [-2.57, -0.22]	Std. Mean Difference IV. Random, 95% Cl	D <u>Study or Subgroup</u> 1.5.1 with rehabilitati Boutiere 2016 Korzhova 2019 Korzhova 2019 Mori 2011 Nisko 1000	rTMS group <u>Mean SD Tota</u> on therapy -28.8 19.6 1 -1 0.55 1 -1.5 1 1 -0.8 0.4 11 -0.6 0.0 0	sham gr <u>I Mean S</u> -10.6 17. -0.2 0.4 -0.2 0.4 -0.4 0.	roup D Total Weig 3 8 10.7 2 5 9.0 2 5 9.1 6 10 11.5 4 17	Std. Mean Difference IV. Random. 95% Cl % -0.93 [-1.95, 0.09] % -1.46 [-2.65, -0.28] % -1.40 [-2.57, -0.22] % -0.75 [-1.67, 0.16]	Std. Mean Difference IV. Random. 95% Cl	
C Study or Subgroup 1.7.1 F/M>1 Centonze 2007 Dieguez-Varela 2019 Korzhova 2019 Korzhova 2019 Mori 2010 Uku 2020	rTMS group Mean SD Tot -2.02 1.7 1 -0.54 0.98 1 -1 0.55 1 -1.5 1 1 -1.76 2.98 1	sham gro al Mean SD 2 0.02 1.69 0 -1.98 1.73 2 -0.2 0.42 2 -0.2 0.42 0 -0.6 1.83	7 7 7 5 5 10	Weight 10.7% 10.4% 9.0% 9.1% 12.2%	Std. Mean Difference IV. Random, 95% Cl -1.15 [-2.17, -0.13] 1.03 [-0.02, 2.07] -1.46 [-2.65, -0.28] -1.40 [-2.57, -0.22] -0.45 [-1.34, 0.44] 0.45 [-0.20, 0.01]	Std. Mean Difference IV. Random. 95% Cl	D <u>Study or Subgroup</u> 1.5.1 with rehabilitati Boutiere 2016 Korzhova 2019 Korzhova 2019 Mori 2011 Nielsen 1996 Sen 2010	rTMS group <u>Mean SD Tota</u> on therapy -28.8 19.6 1 -1 0.55 11 -0.8 0.4 11 -3.5 6.2 2 111 145 11	sham gr <u>I Mean Si</u> -10.6 17. -0.2 0.4 -0.2 0.4 -0.2 0.4 -0.4 0. -1.2 7. 0 0.16 0.5	roup D Total Weig 3 8 10.7 2 5 9.0 2 5 9.1 6 10 11.5 4 17 15.7 2 6 10.7	Std. Mean Difference ht IV. Random, 95% Cl. % -0.93 [-1.95, 0.09] % -1.46 [-2.65, -0.28] % -1.40 [-2.57, -0.22] % -0.75 [-1.67, 0.16] % -0.33 [-0.98, 0.31] % -0.33 [-0.94, 0.31]	Std. Mean Difference IV. Random. 95% Cl	
C Study or Subgroup 1.7.1 F/N>1 Centonze 2007 Dieguez-Varela 2019 Korzhova 2019 Korzhova 2019 Mori 2010 Nielsen 1996 Subtotal (95% CB)	rTMS group <u>Mean</u> <u>SD</u> Tot -2.02 1.7 1 -0.54 0.98 1 -1 0.55 1 -1.5 1 1 -1.76 2.98 1 -3.5 6.2 2	sham gro al Mean SD 2 0.02 1.69 0 -1.98 1.73 2 -0.2 0.42 2 -0.2 0.42 0 -0.6 1.83 1 -1.2 7.4 7	7 7 5 5 10 17	Weight 10.7% 10.4% 9.0% 9.1% 12.2% 15.7% 67.3%	Std. Mean Difference IV. Random, 95% Cl -1.15 [-2.17, -0.13] 1.03 [-0.02, 2.07] -1.46 [-2.65, -0.28] -1.40 [-2.57, -0.22] -0.45 [-1.34, -0.44] -0.33 [-0.98, 0.31] -0.59 [-1.26, 0.09]	Std. Mean Difference IV. Random, 55%. Cl	D Study or Subgroup 1.5.1 with rehabilitati Boutiere 2016 Korzhova 2019 Korzhova 2019 Mori 2011 Nielsen 1996 Şan 2019 Subtotal (95% CI)	rTMS group Mean SD Tota on therapy -28.8 19.6 1 -1.5 1 12 -0.8 0.4 11 -3.5 6.2 2 -1.1 1.45 11 -7	sham gr <u>I Mean</u> SI -10.6 17. -0.2 0.4 -0.2 0.4 -0.2 0.4 0 -0.4 0. I -1.2 7. 0.16 0.8	Total Weig 3 8 10.7 2 5 9.0 2 5 9.1 6 10.11.5 14 4 17 15.7 2 6 10.6 51 66.6	Std. Mean Difference ht IV. Random. 95% Cl % -0.93 [-1.95, 0.09] % -1.46 [-2.65, -0.28] % -1.46 [-2.67, -0.22] % -0.73 [-1.67, 0.16] % -0.33 [-0.90, 0.31] % -0.94 [-2.02, 0.14] % -0.94 [-1.48, -0.41]	Std. Mean Difference IV. Random 35% Cl	
C Study or Subgroup 1.7.1 FIM>1 Centonze 2007 Dieguez.Varela 2019 Korzhova 2019 Korzhova 2019 Mori 2010 Nielsen 1996 Subtotal (85% Cl) Heterogeneity: Tau² =	rTMS group <u>Mean</u> <u>SD</u> Tot -2.02 1.7 1 -0.54 0.98 1 -1 0.55 1 -1.5 1 1 -1.76 2.98 1 -3.5 6.2 2 7 0.46: ChP = 14.84	sham gro al Mean SD 2 0.02 1.69 0 -1.98 1.73 2 -0.2 0.42 2 -0.2 0.42 0 -0.6 1.83 11 -1.2 7.4 7 ff = 5 (P = 0.01	7 7 5 5 10 17 51	Weight 10.7% 10.4% 9.0% 9.1% 12.2% 15.7% 67.3%	Std. Mean Difference IV. Random. 95% Cl -1.15 [-2.17, -0.13] 1.03 [-0.02, 2.07] -1.46 [-2.65, -0.28] -1.40 [-2.57, -0.22] -0.45 [-1.34, 0.44] -0.33 [-0.98, 0.31] -0.59 [-1.26, 0.09]	Std. Mean Officerace IV. Random, 55%. CI	D Study or Subgroup 1.5.1 with rehabilitati Boutière 2016 Korzhova 2019 Korzhova 2019 Mori 2011 Nielsen 1996 Şan 2019 Subtotal (95% CI) Heterogeneity: Tau ² =	rTMS group Mean SD Tota on therapy -28.8 19.6 9 -1 0.55 12 -1.5 1 12 -0.8 0.4 10 -3.5 6.2 2 -1.1 1.45 1 -0.6 0.4 10 -3.5 6.2 3 -0.0 0.0 10 -1.0 -0.5 10 -0.5 10	sham gr <u>I Mean</u> Si -10.6 17. -0.2 0.4 -0.2 0.4 -0.4 0. I -1.2 7. 0.16 0.8 = 5 (P = 0.50)	Total Weig 3 8 10.7 2 5 9.0 2 5 9.1 6 10 11.5 4 17 15.7 2 6 10.6 51 66.6 51 19	Std. Mean Difference IV. Random. 95% Cl % -0.93 [-1.95, 0.09] % -1.46 [-2.65, -0.28] % -1.46 [-2.67, -0.22] % -0.75 [-1.67, 0.16] % -0.33 [-0.96, 0.31] % -0.34 [-2.02, 0.14] % -0.84 [-2.02, 0.14]	Std. Mean Difference IV. Random. 95% Cl	
C Study or Subgroup 1.7.1 F/M>1 Centonze 2007 Dieguez-Varela 2019 Korzhova 2019 Korzhova 2019 Mori 2010 Nielsen 1996 Subtotal (85% CI) Heterogeneity: Tau ² = Test for overall effect:	rTMS group Mean SD Tot -2.02 1.7 1 -0.54 0.98 1 -1 0.55 1 -1.76 2.98 1 -3.5 6.2 2 7 0.46; Chi ^p = 14.84, Z = 1.70 (P = 0.09)	sham gro al Mean SD 2 0.02 1.69 0 -1.98 1.73 2 -0.2 0.42 2 -0.2 0.42 2 -0.2 0.42 0 -0.6 1.83 1 -1.2 7.4 7 ff = 5 (P = 0.01	7 7 5 5 10 17 51); I ² = 66	Weight 10.7% 10.4% 9.0% 9.1% 12.2% 15.7% 67.3%	Std. Mean Difference IV. Random. 95% Cl -1.15 [-2.17, -0.13] 1.03 [-0.02, 2.07] -1.46 [-2.65, -0.28] -1.40 [-2.57, -0.22] -0.45 [-1.34, 0.44] -0.33 [-0.98, 0.31] -0.59 [-1.26, 0.09]	Std. Mean Difference IV. Random, 85% CI	D Study or Subgroup 1.5.1 with rehabilitati Boutiere 2016 Korzhova 2019 Mori 2011 Nielsen 1996 Şan 2019 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect:	rTMS group <u>Mean SD Tota</u> on therapy -28.8 19.6 19 -1 0.55 12 -1.5 1 11 -3.5 6.2 2 -1.1 1.45 11 7 0.00; Chi ² = 4.36, df Z = 4.09 (P < 0.0001	sham gr 1 Mean Si 0 -10.6 17. 2 -0.2 0.4 2 -0.2 0.4 0 -0.4 0. 1 -1.2 7. 0 0.16 0.8 4 5 (P = 0.50))	Total Weig 0 Total Weig 2 5 9.0 2 5 9.1 6 10 11.5 4 17 15.7 2 6 10.0 51 66.6 51 96.9	Std. Mean Difference IV. Random. 95% Cl % -0.93 [-1.95, 0.09] % -1.46 [-2.65, -0.28] % -1.46 [-2.67, -0.28] % -0.75 [-1.67, 0.16] % -0.36 [-0.98, 0.31] % -0.34 [-2.02, 0.14] % -0.80 [-1.18, -0.41]	Std. Mean Olffrence IV. Random. 95% Cl	
C Study or Subgroup 1.7.1 F/M>1 Centonze 2007 Dieguez-Varela 2019 Korzhova	rTMS group Mean SD Tot -2.02 1.7 1 -0.54 0.98 1 -1.0.55 1 1 -1.76 2.98 1 -3.5 6.2 2 7 0.46; Chi ^p = 14.84, Z = 1.70 (P = 0.09)	sham gro 2 0.02 1.69 0 -1.98 1.73 2 -0.2 0.42 2 -0.2 0.42 0 -0.6 1.83 11 -1.2 7.4 7 ff = 5 (P = 0.01	7 7 5 5 10 17 51); l ² = 66	Weight 10.7% 10.4% 9.0% 9.1% 12.2% 15.7% 67.3%	Std. Mean Difference (V. Random. 95%; Cl -1.15 [-2.17, -0.13] 1.03 [-0.02, 2.07] -1.46 [-2.65, -0.28] -1.40 [-2.57, -0.22] -0.45 [-1.34, 0.44] -0.33 [-0.38, 0.31] -0.59 [-1.26, 0.09]	Std. Mean Difference IV. Random, 355, Cl	D Study or Subgroup 1.5.1 with rehabilitati Boultiere 2016 Korzhowa 2019 Korzhowa 2019 Korzhowa 2019 Korzhowa 2019 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect 1.5.2 without rehabili	rTMS group <u>Mean SD Tota</u> on therapy -28.8 19.6 9 -1.0,55 11 -0.8 0.4 11 -3.5 6.2 2 -1.1 1.45 11 -0.00; Chi ² = 4.36, df Z = 4.09 (P < 0.0001 tation therapy	sham gr 1 Mean Si 0 -10.6 17. 2 -0.2 0.4 2 -0.2 0.4 0 -0.4 0. 1 -1.2 7. 0 0.16 0.8 5 (P = 0.50))	Total Weig 0 Total Weig 3 8 10.7 2 5 9.0 2 5 9.1 6 10 11.5 4 17 15.7 2 6 10.6 51 66.6 51 6 10% 51	Std. Mean Difference IV. Random. 85% CI 0.93 [-195,0.09] -0.93 [-195,0.08] -1.46 [2.57,-0.28] % -1.40 [2.57,-0.28] % -0.75 [-167,0.16] % -0.33 [-0.98,0.31] % -0.40 [-2.02,0.14] % -0.80 [-1.18,-0.41]	Std. Mean Difference IV. Random 35% Cl	
C Study or Subgroup 1.7.1 F/M→1 Centonze 2007 Dieguez-Varela 2019 Korzhova 2019 Korzhova 2019 Korzhova 2019 Nielsen 1996 Subtotal (85% Cl) Heterogeneity: Tau² = Test for overall effect: 1.7.2 F/M≤1 Boutière 2016	rTMS group <u>Mean SD Tot</u> -2.02 1.7 1 -0.54 0.98 1 -1 0.55 1 -1.5 1 -1.76 2.98 1 -3.5 6.2 2 0.46; Chi ^p = 14.84, Z = 1.70 (P = 0.09) -28.8 19.6	sham gro al Mean SD 2 0.02 1.69 0 -1.98 1.73 2 -0.2 0.42 2 -0.2 0.42 0 -0.6 1.63 11 -1.2 7.4 7 if = 5 (P = 0.01 9 -10.6 17.3	7 7 5 5 10 17 51 51 51 27 8	Weight 10.7% 10.4% 9.0% 9.1% 12.2% 15.7% 67.3%	Std. Mean Difference <u>IV. Random. 95% CI</u> -1.15 [-2.170.13] 1.03 [-0.02, 2.07] -1.46 [-2.650.28] -1.40 [-2.650.22] -1.40 [-2.650.22] -0.45 [-1.34, 0.44] -0.33 [-0.98, 0.31] -0.59 [-1.26, 0.09] -0.93 [-1.95, 0.09]	Std. Mean Difference IV. Random, 85% CI	D Study or Subgroup 1.5.1 with rehabilitati Bouliere 2016 Korzhova 2019 Mori 2011 Nielsen 1996 Şan 2019 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 1.5.2 without rehabili Centoraz 2007	rTMS group <u>Mean SD Tots</u> on therapy -1 0.55 11 -0.8 0.4 11 -0.8 0.4 11 -0.8 0.4 11 -0.8 0.4 11 -1.1 1.45 11 -0.00, ChP = 4.36, dP -2.00 1.7 11	sham gr 1 Mean Si 2 -0.2 0.4 2 -0.2 0.4 0 -0.4 0. 1 -1.2 7. 0 -1.2 7. 0 -1.6 0.8 4 5 (P = 0.50) 2 0.02 1.6	Total Weig 3 8 10.7 2 5 9.0 2 5 9.1 6 10 11.5 2 6 10.0 5 6.6 10 51 66.4 51 9 7 10.7	Std. Mean Difference IV. Random. 95% CI % -0.93 [-1.95, 0.09] ~1.46 [2.26, -0.28] % -1.40 [2.27, -0.22] ~0.75 [-167, 0.16] % -0.33 [-0.96, 0.31] % -0.40 [2.20, 0.14] % -0.15 [2.17, -0.13]	Stut. Mean Olffrence IV. Random. 95% Cl	
C Study or Subgroup 1.7.1 F/M>1 Centonze 2007 Dieguez-Varela 2019 Korzhova 2019 Korzhova 2019 Korzhova 2019 Mori 2010 Nieisen 1996 Subtotal (95% CI) Heterogeneity: Tau ³ = Test for overall effect: 1.7.2 F/M≤1 Boutiere 2016 Mori 2011	rTMS group Mean SD Tot -2.02 1.7 1 -1.0.55 40.98 1 -1.0.55 1 -1.76 2.98 1 -3.5 6.2 2 0.46; Chi ^p = 14.84, Z = 1.70 (P = 0.09) -28.8 19.6 -0.8 0.4 1	sham gro al Mean SD 2 0.02 1.69 0 -1.98 1.73 2 -0.2 0.42 2 -0.2 0.42 2 -0.2 0.42 0 -0.6 1.83 1 -1.2 7.4 7 ff = 5 (P = 0.01 9 -10.6 17.3 0 -0.4 0.6	7 7 5 5 10 17 51); ² = 66	Weight 10.7% 10.4% 9.0% 9.1% 12.2% 15.7% 67.3% %	Std. Mean Difference IV. Random. 95%; CI -1.15 [-2.17, -0.13] 1.03 [-0.02, 2.07] -1.46 [-2.65, -0.28] -1.40 [-2.57, -0.22] -0.45 [-1.34, 0.44] -0.33 [-0.98, 0.31] -0.59 [-1.26, 0.09] -0.93 [-1.95, 0.09] -0.75 [-1.67, 0.16]	Std. Mean Difference IV. Random 355 Cl	D Study or Subgroup 1.5.1 with rehabilitati Boulière 2016 Korzhova 2019 Korzhova 2019 Korzhova 2019 Korzhova 2019 Subtotal (95% Cl) Heterogeneity: Tau ⁺ = Test for overall effect: 1.5.2 without rehabilit Centorze 2007 Dieguez: Varela 2019 Dieguez: Varela 2019	TTMS group Maan SD Toto on therapy -28.8 19.6 1 -10.55 11 -1 -1 1 1 -1.8 0.4 1 1 -1	sham gr Mean Si -10.6 17. 2 -0.2 0.4 2 -0.2 0.4 2 -0.2 0.4 0 -1.2 7. 0 0.16 0.8 5 (P = 0.50) 2 0.02 1.6 0 -1.98 1.7 -0.2 0.4 -1.2 7. 0 0.16 0.8 -1.2 7. 0 0.02 1.6 0.8 -1.0 7. 0 0.00 1.6 0.8 -1.0 7. 0 0.00 1.6 0.8 -1.0 7. 0 0.0 7	Total Weig 3 8 10.7 2 5 9.0 2 5 9.1 6 10 11.5 4 17 15.7 2 6 10.0 51 66.0 51 66.0 9 7 10.3 3 7 10.4 2 0 10.4	Std. Mean Difference tr. V. Random. 82% CI -0.321 (195.009) -1.46 [2.2650.22] -1.46 [2.2670.22] -0.37 [-1.67.0.18] -0.34 [-2.02.0.14] % -0.34 [-2.02.0.14] % -0.36 [-1.180.41] % -1.15 [-2.170.13] % -1.03 [-0.02, 2.07]	Std. Mean Ofference IV. Random. 35% Cl	
C Study or Subgroup 17.1 F/MM1 Centorize 2007 Dieguez-Varela 2019 Korzhova 2019 Korzhova 2019 Mori 2010 Nielsen 1996 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 17.2 F/MG1 Bouliere 2016 Mori 2011 San 2019	rTMS group <u>Mean SD Tot</u> -2.02 1.7 1 -0.54 0.98 1 -1 0.55 1 -1.5 1 -1.5 2.98 1 -3.5 6.2 2 7 0.46; ChP = 14.84, Z = 1.70 (P = 0.09) -28.8 19.6 -0.8 0.4 1 -1.1 1.45 1	sham gro al Mean SD 2 0.02 1.69 0 -1.98 1.73 2 -0.2 0.42 2 -0.2 0.42 2 -0.2 0.42 0 -0.6 1.83 1 -1.2 7.4 7 ff = 5 (P = 0.01 9 -10.6 17.3 0 -0.4 0.82	yup 7 7 5 10 17 51); ² = 66 8 10 6	Weight 10.7% 10.4% 9.0% 9.1% 12.2% 15.7% 67.3% 15.7% 10.7% 11.9% 10.0%	Std. Mean Difference IV. Random. 95% Cl -1.15 [-2.17, -0.13] 1.03 [-0.02, 2.07] -1.46 [-2.65, -0.28] -1.40 [-2.57, -0.22] -0.45 [-1.34, 0.44] -0.33 [-0.86, 0.31] -0.39 [-1.26, 0.09] -0.93 [-1.95, 0.09] -0.75 [-1.67, 0.16] -0.94 [-2.02, 0.14]	Std. Mean Difference IV. Random, 85% CI	D Study or Subgroup 1.5.1 with rehabilitati Bouliere 2016 Korzhova 2019 Korzhova 2019 Korzhova 2019 Mori 2011 Nielsen 1996 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 1.5.2 without rehabili Centionze 2007 Dieguez-Warela 2019 Mori 2010	rTMS group Maan SD Totas on therapy -28.8 19.6 c ⁻¹ -1 0.55 1 -1.5 1 1 -0.8 0.4 11 -0.8 0.4 11 -0.8 0.4 11 -0.7 0.00 ChP = 4.36, dP -0.00 ChP = 4.36, dP -0.00 ChP = 4.36, dP -0.00 ChP = 4.36, dP -0.054 0.98 11 -1.76 2.98 12 -0.76 0.98 11 -0.76 0.98 0.98 11 -0.76 0.98 0.98 11 -0.76 0.98 0.98 11 -0.76 0.98 0.98 0.98 0.98 0.98 0.98 0.98 0.98	sham gr Mean SI 0 -10.6 17. 2 -0.2 0.4 2 -0.2 0.4 2 -0.2 0.4 0 -0.4 0.1 1 -1.2 7. 0 0.16 0.8 5 (P = 0.50) 2 0.02 1.6 0 -1.98 1.7 0 -0.6 1.8	Total Weig 3 8 10.7 2 5 9.0 2 5 9.1 2 5 9.1 4 17 15.7 2 6 10.0 51 66.4); I' = 0% 9 7 10.7 3 7 10.4 3 10 12.2 24 12 24	Std. Mean Difference IV. Random. 95% CI % -0.93 [-1.95, 0.09] ~1.46 [-2.45, -0.28] % -1.46 [-2.45, -0.28] % -1.46 [-2.7, -0.22] % -0.75 [-167, 0.16] % -0.33 [-0.96, 0.31] % -0.86 [-1.18, -0.41] % -1.15 [-2.17, -0.13] % -1.15 [-2.17, -0.13] % -0.46 [-1.34, 0.44]	Stut. Mean Olffrence IV. Random. 95% Cl	
C Study or Subgroup 1.7.1 F/MM1 Centonze 2007 Dieguez-Varela 2019 Korzhova 2019 Korzhova 2019 Korzhova 2019 Korzhova 2019 Mori 2010 Nielsan 1996 Subtotal (65% C) Heterogeneity-Tau ⁺ ≡ Test for overall effect: 1.7.2 F/M ≤1 Boutiere 2016 Mori 2011 San 2019 Subtotal (65% C)	rTMS group Mean SD Tot -2.02 1.7 1 -1 0.55 1 -1.055 1 -1.76 2.88 1 -3.5 6.2 2 7 0.46; Chi ^p = 14.84, Z = 1.70 (P = 0.09) -28.8 19.6 -0.8 0.4 1 -1.1 1.45 1 -1.1 1.45 1	sham gro al Mean SD 2 0.02 1.69 0 -1.98 1.73 2 -0.2 0.42 2 -0.2 0.42 0 -0.6 1.83 1 -1.2 7.4 7 ff = 5 (P = 0.01 9 -10.6 17.3 0 -0.4 0.6 9 -10.6 0.82 9	7 7 5 5 10 17 51); I ² = 66 8 10 6 24	Weight 10.7% 10.4% 9.0% 12.2% 15.7% 67.3% 1%	Std. Mean Difference IV. Random. 95%, CI -1.15; 2.17, 0.13; -1.03; [-0.02, 2.07] -1.46; [-265, -0.28] -1.46; [-265, -0.28] -0.45; [-1.34, 0.44] -0.33; [-0.98, 0.31] -0.59; [-1.26, 0.09] -0.59; [-1.26, 0.09] -0.75; [-1.67, 0.16] -0.88; [-1.44, -0.28]	Std. Mean Difference IV. Random, 355 Cl	D Study or Subgroup 1.5.1 with rehabilitati Bootire 2016 Korzhowa 2019 Korzhowa 2019 Korzhowa 2019 Korzhowa 2019 Korzhowa 2019 Nieteon 1996 San 2019 Subtotal (89% CI) Heterogenety: Tau ⁺ = Test for overall effect 1.5.2 without rehability Centoriza 2007 Dieguez-Varela 2019 Dieguez-Varela 2019 Stubtotal (89% CI) Stubtotal (89% CI) Stubtotal (89% CI) Stubtotal (89% CI) Stubtotal (89% CI) Stubtotal (89% CI)	$\begin{array}{c} \text{rTMS group} \\ \underline{\text{Mean}} & \text{SD} & \text{Tote} \\ \text{on therapy} \\ -28.8 & 19.6 & -1 \\ -1 & 0.55 & 11 \\ -1.5 & 1 & 11 \\ -0.8 & 0.4 & 11 \\ -3.5 & 6.2 & 2 \\ -1.1 & 1.45 & 11 \\ 7 \\ 0.00; \text{ChP} = 4.36, \text{ eff} \\ 2 = 4.09 (P < 0.0001 \\ \text{tation therapy} \\ -2.02 & 1.7 & 11 \\ -1.76 & 2.98 & 11 \\ -1.76 & 2.98 & 11 \\ 0.87; \text{ChP} = 8.33, \text{eff} \\ -8.33 & -1.76 \\ -1.76 & -2.88 & 11 \\ -1.76 & -2.88 & 11 \\ -1.76 & -2.88 & 11 \\ -1.76 & -2.88 & 11 \\ -1.76 & -2.88 & 11 \\ -1.76 & -2.88 & 11 \\ -1.76 & -2.88 & 11 \\ -1.76 & -2.88 & 11 \\ -1.76 & -2.88 & 11 \\ -1.76 & -2.88 & 11 \\ -1.76 & -2.88 & 11 \\ -1.76 & -2.88 & 11 \\ -1.76 & -2.88 & 11 \\ -1.76 & -2.88 & 11 \\ -1.76 & -2.88 & 11 \\ -1.76 & -2.88 & 11 \\ -1.76 & -2.88 & 11 \\ -1.76 & -2.88 & 11 \\ -1.76 & -2.88 & -2.88 \\ -1.76 & -2.8$	sham gr Mean Si 	Total Weig 3 8 10.7 2 5 9.0 6 10 11.5 4 17 15.7 2 6 10.0 51 66.0); P = 0% 9 7 10.7 3 7 10.4 3 10 12.2 24 33.4); P = 78%	Std. Mean Difference tr. V. Random. 925.CI -0.321.F05.009 -1.46 [2.265022] -1.46 [2.267022] % -0.371.F167.018] ~0.34 [-2.02.014] % -0.34 [-2.02.014] % -0.34 [-2.02.014] % -0.34 [-2.02.014] % -0.34 [-2.02.014] % -0.34 [-3.13.044] % -0.36 [-1.14.044]	Std. Mean Ofference IV. Random. 35% Cl	
C Study or Subgroup 1.7.1 F/MM1 Centonze 2007 Dieguez-Varela 2019 Korzhova 2019 Korzhova 2019 Korzhova 2019 Korzhova 2019 Korzhova 2019 Mori 2010 Nielsan 1996 Subtotal (85% CI) Bouliera 2016 Mori 2011 San 2019 Subtotal (85% CI) Heterogeneity, Tau ² = Test for overall effect:	rTMS group Maan SD Tot -2.02 1.7 1 -0.54 0.88 1 -1 0.55 1 1 -1.76 2.98 1 -1.6 2.98 1 -1.70 (P = 0.09) -28.8 19.6 -0.8 0.4 1 -1.1 1.45 1 -0.11 1.45 2 0.00; ChP = 0.10, dl Z = 2.94 (P = 0.003)	sham gra al Mean SD 2 0.02 1.69 0 -1.98 1.73 2 0-20 42 2 -0.2 0.42 2 -0.2 0.42 1 -1.2 7.4 7 ff = 5 (P = 0.01 9 -10.6 17.3 0 -0.4 0.6 0 0.16 0.82 9 = 2 (P = 0.95);	7 7 5 5 10 17 51); ² = 66 8 10 6 24 ² = 0%	Weight 10.7% 10.4% 9.0% 9.1% 12.2% 15.7% 67.3% %	Std. Mean Difference (Y. Bandom, 85% CI 115 [247, -0.13] 100 [402, 247] 144 [265, -0.28] 144 [265, -0.28] -146 [247, -0.22] -0.45 [-134, 0.44] -0.35 [-1.28, 0.09] -0.33 [-1.98, 0.09] -0.33 [-1.98, 0.09] -0.34 [2.02, 0.14] -0.36 [-1.44, -0.23]	Std. Mean Difference IV. Random 35% CI	D Budy or Subgroun. 1.5.1 with rehabilitati Boulaire 2010 Source 2019 Mori 2011 Nieteen 1996 San 2019 Subtotal (95% CI) Heterogeneily: Tar /= Subtotal (95% CI) Heterogeneily: Tar /= Test for overall effect: Test for overall effect:	TMS group Mean SD Total -28.8 19.6 - -1 0.55 1: -1.5 1 1: -0.8 0.4 11 -3.5 6.2 2 -1.1 1.45 1 0.00: Chi² = 4.36, df 2 4.09 (P < 0.0001	sham gr I Mean Si 9 -10.6 17. 2 -0.2 0.4 2 -0.2 0.4 1 -1.2 7. 0 -0.6 0.8 4 5 (P = 0.50.) 2 0.02 1.6 0 -1.98 1.7 0 -0.6 1.8 = 2 (P = 0.01.	Total Weig 0 Total Weig 2 5 9.1 2 5 9.1 2 5 9.1 3 10.7 10.1 4 17 15.7 2 6 10.0 51 66.4 9 7 10.3 3 10 12.2 24 33.4 24 33.4); I ² = 78% 10	Std. Mean Difference ht IV. Random. 35% CI with IV. Random. 35% CI <td>Std. Mean Difference IV. Random. 95% CI</td> <td></td>	Std. Mean Difference IV. Random. 95% CI	
C Study or Subgroup	rTMS group Maan SD Tot -2.02 1.7 1 -0.54 0.98 1 -1 0.55 1 -1.5 1 -1.76 2.98 1 -3.5 6.2 2 0.46; Chi ^p = 14.84, Z = 1.70 (P = 0.04) -28.8 19.6 -0.8 0.4 1 -1.1 1.45 1 2 0.00; Chi ^p = 0.01, d Z = 2.94 (P = 0.003)	sham gra al Mean SD 2 0.02 1.69 0 -1.98 1.73 2 -0.2 0.42 2 -0.2 0.42 2 -0.2 0.42 1 -0.2 0.42 1 -1.2 7.4 if = 5 (P = 0.01 9 -10.6 17.3 0 -0.4 0.60 0 -10.6 17.3 9 = 2 (P = 0.95); 6	Pup Total 7 5 5 10 17 51); ² = 66 8 10 6 24 ² = 0% 75	Weight 10.7% 10.4% 9.0% 9.1% 12.2% 67.3% 15.7% 67.3% 10.7% 11.9% 10.0% 32.7% 100.0%	Sta Maran Difference IV. Random, 89% CI 115 [-217, -0.13] 1.09 [-0.02, 207] 1.46 [-265, -0.28] 1.46 [-265, -0.28] 1.46 [-27, -0.22] 0.45 [-134, 0.44] -0.45 [-134, 0.44] -0.45 [-148, 0.49] -0.95 [-1.68, 0.09] -0.75 [-1.68, 0.09] -0.75 [-1.68, 0.09] -0.58 [-1.48, -0.29] -0.58 [-1.44, -0.29] -0.58 [-1.44, -0.29]	Std. Mean Difference IV. Random, 85% CI	Budy or Subprove. 1.5.1 with rehabilities Boutiere 2016 Korzhova 2019 Korzhova 2019 Mol 2011 Nieteen 1966 San 2019 San 2019 Heterogeneity; Tauf = Test for overall effect: 1.5.2 without rehability Heterogeneity; Tauf = Test for overall effect: Test for overall effe	TTMS group and SD Tots on therapy -28.8 19.6 -15 -15 -16 -17 -18 -19.8 -11 -14.9 -11 -12.8.4 -11 -12.8 -11.1 -12.2 -1.1 -1.1 -2.00 -2.02 -1.1 -2.02 -1.1 -2.02 -1.1 -2.02 -1.1 -2.02 -2.02 -1.7 -2.05 -0.05 -0.54 -0.54 -0.54 -0.7 -1.76 -1.8 -1.76 -2.03 -2.03 -2.03 -2.04 -1.4 -1.76	sham gr I Mean Si 3 -10.6 17. 2 -0.2 0.4 2 -0.2 0.4 0 -0.4 0. 1 -1.2 7. 0 0.16 0.8 5 (P = 0.50) 2 0.02 1.6 0 -1.98 1.7 0 -1.96 1.8 2 2 (P = 0.01) 3	D Total Weig D Total Weig 3 8 10.7 2 5 9.0 2 5 9.0 2 5 9.0 4 17 15.7 5 1 17 51 66.4 10.0 9 7 10.0 9 7 10.4 24 33.4 10 12.2 24 33.4 10 78 100.0 100.1	Std. Mean Difference. ht VX Random, 95% CI. VX Random, 95% CI. 0.03 vi Alago 1.46 [2.65, -0.28] vi - 1.46 [2.65, -0.28] -0.33 [0.36, 0.31] vi - 0.34 [-2.02, 0.14] -0.34 [-2.02, 0.14] vi1.16 [-2.17, -0.13] -0.34 [-2.02, 0.14] vi1.15 [-2.17, -0.13] -0.34 [-2.02, 0.14] vi1.15 [-2.17, -0.13] -0.42 [-1.40, 1.00] vi2.26 [-1.40, 1.00] -0.26 [-1.40, 1.00]	Stut. Mean Olffrence IV. Random. 95% Cl	
C Study ar Subgroup 1.7.1 F/M-1 Centones 2007 Decremon 2010 Decremon 2010 Norison 2010 Norison 2010 Nuelsen 1996 Subbtati (85% CI) Heterogeneity: Tau ² = Test for overall effect: 1.7.2 F/M <1 Boutiere 2016 Mori 2011 Subbtati (85% CI) Heterogeneity: Tau ² = Test for overall effect: Total (85% CI)	rTMS group Maan SD Tot -2.02 1.7 1 -0.54 0.98 1 -1.055 1 -1.76 2.98 1 -1.76 2.98 1 -1.76 2.98 1 -2.88 19.6 -0.8 0.4 1 -1.11 1.45 1 0.00; Chi ² = 0.10, dl Z = 2.94 (P = 0.003) 0.24; Chi ² = 15.93, 3 -0.04; Chi ² = 15.94, 4 -0.04; Chi ²	sham gra al Mean SD 2 0.02 1.69 0 -1.98 1.73 2 -0.2 0.42 2 -0.2 0.42 0 -0.6 1.83 1 -1.2 7.4 7 f = 5 (P = 0.01 9 -10.6 17.3 0 -0.4 0.6 0 0.16 0.82 9 = 2 (P = 0.95); 6 f = 8 (P = 0.04	7 7 5 10 17 51 17 51 17 51 17 51 17 8 10 6 24 10 6 24 10 6 24 10 6 24 10 75 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	Weight 10.7% 9.0% 9.1% 12.2% 15.7% 67.3% % 10.7% 11.9% 10.0% 32.7% 100.0%	Stat Mara Difference IV. Bandom, 855 CI -115 [-217, -0.13] 1.09 [-0.02, 2.07] 1.46 [-26, -0.28] -1.46 [-26, -0.28] -1.46 [-26, -0.28] -1.46 [-26, -0.28] -0.35 [-14, -0.21] -0.35 [-14, -0.21] -0.35 [-14, -0.59] -0.35 [-14, -0.23] -0.86 [-1.44, -0.23] -0.67 [-1.12, -0.21]	Std. Man Difference IV. Random 35% CI	D Budy or Subgroun. 1.5.1 with rehabilitati Boulaive 2016 Source 2016 Korzhova 2019 Mori 2011 Nielsen 1996 San 2019 Subtotal (95% CI) Heterogeneity, Tau ⁺ Test for overall effect: 1.5.2 without rehabili Contrava 2020 Digues Avente 2019 Mori 2010 Subtotal (95% CI) Heterogeneity, Tau ⁺ Test for overall effect: Total (95% CI)	$\begin{array}{c} \text{rTMS group}\\ \hline \text{max} \text{SD Totic}\\ \text{max} \text{SD Totic}\\ -28.8 \ 19.6 \text{max}\\ -1 0.55 1 1 \\ -1.5 1 1 \\ -3.5 6.2 2 \\ -1.1 1.45 1 \\ -3.5 6.2 2 \\ -1.1 1.45 1 \\ -3.6 0.6 0.6 0.0001\\ \hline \text{tation therapy}\\ -2.02 1.7 1 \\ -2.02 1.7 1 \\ -2.02 1.7 1 \\ -2.02 1.7 1 \\ -2.02 1.7 1 \\ -1.76 2.98 1 \\ 0.67; \ \text{Chi}^{2} = 8.93, \text{eff}\\ Z = 0.33 \ (\text{P} = 0.74)\\ 0.24; \ \text{Chi}^{2} = 5.93, \text{eff}\\ 0.24; \ \text{Chi}^{2} = 5.93, \text{eff}\\ \end{array}$	sham gr I Mean Si - 10.6 17. 2 -0.2 0.4 0.4 0. 1 -1.2 7. 0 0.16 0.8 = 5 (P = 0.50 - 1.98 1.7 - 0.6 1.8 = 2 (P = 0.01 = 2 (P = 0.01) = 3 (P = 0.02)	Point Waig D. Total Waig D. Total Waig 3 8 10.7 2 5 9.6 2 5 9.6 4 17 15.7 5 10.7 51 66.4 9 7 10.7 3 10 12.2 24 33.7 10.4 3.4 12 24 3.4 ½ P = 78% 75 100.6 4); P = 50% 75 100.7 10.7 10.7	Std. Mean Difference. ht IV. Random. 35% CI w. 0.33 (1.45, 0.09) -0.33 (1.45, 0.09) % -1.46 [2.45, -0.22] -0.73 [1.67, 0.51] % -0.73 [1.67, 0.51] -0.42 (2.20, 0.14] % -0.48 [2.17, -0.13] -0.48 (2.20, 0.14] % -1.16 [2.17, -0.13] -0.45 [1.34, 0.44] % -0.45 [1.34, 0.44] -0.20 [1.44, 0.46]	Std. Mean Difference	
C Study or Subgroup. 17.1 FMM1 Centorse 2007 Diegues-Varela 2019 Korzhova 2019 Korzhova 2019 Korzhova 2019 Korzhova 2019 Subbotal (1955 CI) Heterogeneity: Tau ² = Boutilera 2016 Mori 2011 San 2019 Subbotal (195% CI) Heterogeneity: Tau ² = Test for overall effect: Test for overall effect: Test for overall effect: Test for overall effect: Test for overall effect:	rTMS group <u>Man</u> SD Tot -2.02 1.7 1 -1.0.55 1.0.88 1 -1.0.55 1.1 -1.75 2.98 1 -1.75 2.98 1 -3.5 6.2 2 0.46; Chi ⁿ = 14.84, 1 -28.8 19.6 -0.8 0.4 1 -1.1 1.45 1 2 0.00; Chi ⁿ = 0.10, 0 2 2.94 (P = 0.004) 10.24; Chi ⁿ = 15.93, 10 -2.86 (P = 0.004)	sham gra al Mean SD 2 0.02 1.66 0 -1.98 1.73 2 -0.2 0.42 0 -0.6 1.83 1 -1.2 7.4 ff = 5 (P = 0.01 9 -10.6 17.3 0 -0.4 0.6 0 -0.6 18.3 9 -10.6 17.3 0 -0.4 0.6 9 -10.6 17.3 0 -0.4 0.6 9 -10.6 17.3 1 -1.2 7.4 ff = 5 (P = 0.01 1 -1.2 7.4 9 -10.6 17.3 1 -1.2 7.4 1 -1	7 5 5 10 17 51 31 51 51 51 51 51 51 51 51 51 51 51 51 51	Weight 10.7% 10.4% 9.0% 9.1% 12.2% 15.7% 67.3% 5% 10.7% 10.7% 10.7% 32.7%	Sta Maran Difference IV. Random, 95% CI 115 [-217, -0.13] 109 [-0.02, 207] 1.46 [-265, -0.28] 1.46 [-265, -0.28] 1.46 [-265, -0.28] 1.46 [-27, -0.22] 0.45 [-134, 0.44] -0.35 [-128, 0.09] -0.59 [-128, 0.09] -0.59 [-128, 0.09] -0.54 [-147, 0.16] -0.54 [-147, 0.16] -0.54 [-144, -0.29] -0.67 [-1.12, -0.21]	Std. Mean Difference IV. Random 85% CI	Budy or Subprove. 1.5.1 with rehabilities Boutiere 2016 Korzhova 2019 Korzhova 2019 Mol 2011 Nieteen 1996 San 2019 Mol 2011 Nieteen 1996 San 2019 Korzhova 2019 Mol 2019 Hieterogeneity; Tauf = Test for overall effect: Test for overall effect:	rTMS group on therapy -28.8 [19.6] -15.9 [19.6] -15.9 [19.6] -15.9 [19.6] -15.9 [19.6] -15.9 [19.6] -16.9 [19.6] -17.9 [19.6] -18.0 [19.6] -11.1 [14.5] 0.00; ChF = 4.36, df 2.4.09 [P < 0.0001]	sham gr Mean Si 2 -0.2 0.4 2 -0.2 0.4 2 -0.2 0.4 0 -0.4 0.1 1 -1.2 7, 0 0.16 0.8 4 5 (P = 0.50) 2 0.02 1.6 0 -1.98 1.7 0 -0.6 1.8 = 2 (P = 0.01) 5 5 5 6 5 7 1 1 1 1 1 1 1 1 1 1 1 1 1	Total Weig D. Total Weig D. Total Weig State 10.7 2 5 9.7 2 5 10.1 4 17 15.7 5 10.1 51 6 10.5 51 9 7 10.7 3 10 12.2 2 43.3 7 75 100.0 4): I ² = 50% 75 100.2	Std. Mean Difference. ht VX.Random. 95% CI. VX.Random. 95% CI. 0.03 with an obsection of the second sec	Skil. Mean Olffrence IV. Random. 95% CI	
C Study at Subgroup 1.7.1 F/M-1 Centones 2007 Rozchova 2019 Korzchova 2019 Korzchova 2019 Korzchova 2019 Korzchova 2019 Nielsen 1996 Subbotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Total (95% CI) Heterogeneity: Tau ² =	$\begin{array}{c} \text{TMS group} \\ \text{Mean SD Tot} \\ \text{Mean SD Tot} \\ -2.02 & 1.7 \\ -2.02 & 1.7 \\ -1.0 & 2.5 \\ -1.5 & 1.1 \\ -1.76 & 2.86 \\ -1.76 & 2.86 \\ -1.76 & 2.86 \\ -2.7 \\ -2.85 & 1.96 \\ -2.85 & 1$	sham grc al Mean SD 2 0.02 1.69 0 -1.98 1.73 2 -0.2 0.42 0 -0.6 1.83 11 -1.2 7.4 ff = 5 (P = 0.01 9 -10.6 17.3 0 -0.4 0.6 0 0.16 0.82 9 = 2 (P = 0.95); 6 ff = 8 (P = 0.04 df = 1 (P = 0.5	yup Total 7 7 5 5 10 17 51 17 51 18 0 6 24 12 12 75 55 10 6 24 12 75 <t< td=""><td>Weight 10.7% 10.4% 9.0% 9.1% 12.2% 15.7% 67.3% 67.3% 10.7% 11.9% 10.0% 32.7% 100.0% 1%</td><td>Star. Maen Difference IV. Bandom, 855 CI -115 [-217, -0.13] 1.09 [-0.02, 2.07] 1.46 [-26, -0.28] -1.46 [-26, -0.28] -1.46 [-26, -0.28] -1.46 [-26, -0.28] -0.35 [-14, -0.21] -0.35 [-14, -0.59] -0.35 [-14, -0.59] -0.35 [-14, -0.28] -0.86 [-1.44, -0.28] -0.67 [-1.12, -0.21]</td><td>Std. Man Difference IV. Random 35% CI</td><td>Budy or Subprove 1.1.1 with rehabilities Boutier 2016 Korzhowa 2019 Korzłowa 2019 Korzłowa 2019 Korzłowa 2019 Korzłowa 2019 Korzłowa 2019 Korzłowa 2019 Korzłowa 2019 Korzych (C) Heterogenejky, Tau⁺ Test for overali effect: Total (6%; C) Heterogenejky, Tau⁺ Test for overali effect: Total (6%; C) Test for overali effect: Total (6%; C) Test for overali effect: Test for overali effect</td><td>$\begin{array}{rrrr} TMS \ group \\ Maan & SD & Tota \\ Maan & SD & Tota \\ -8.8 & 19.6 & 1.2 \\ -3.8 & 19.6 & 1.2 \\ -3.8 & 19.6 & 1.2 \\ -3.8 & 0.4 & 1.1 \\ -3.5 & 6.2 & 2 \\ -1.1 & 1.45 & 1.1 \\ -3.5 & 6.2 & 2 \\ -1.1 & 1.45 & 1.1 \\ -3.5 & 6.2 & 2 \\ -1.1 & 1.45 & 1.1 \\ -3.5 & 4.39 & (P & 0.0001 \\ -3.5 & 4.39 & (P & 0.0011 \\ -3.5 & -3.5 & -3.5 \\ -3$</td><td>sham gr 1 Mean Si 2 -0.2 0.4 2 -0.2 0.4 2 -0.2 0.4 2 -0.2 0.4 0 -0.4 0.4 -1.2 7. 0 0.16 0.8 5 (P = 0.50) -1.8 1.7 0 -0.6 1.8 2 0.02 1.6 0 -1.98 1.7 3 4 = 8 (P = 0.0 df = 1 (P = 0.2) df = 1 (P = 0.2)</td><td>Poing D Total Weig D Total Weig No D Total Weig No 3 8 10.7. S S 2 5 9.6 No S S 4 17 15.7 S</td><td>Std. Mean Difference. ht IV. Random. 35% CI. ht IV. IV. Random. 35% CI. ht IV. IV. Random. 35% CI. ht IV. Random. 35% CI.</td><td>Std. Mean Difference IV. Random. 95% CI</td><td></td></t<>	Weight 10.7% 10.4% 9.0% 9.1% 12.2% 15.7% 67.3% 67.3% 10.7% 11.9% 10.0% 32.7% 100.0% 1%	Star. Maen Difference IV. Bandom, 855 CI -115 [-217, -0.13] 1.09 [-0.02, 2.07] 1.46 [-26, -0.28] -1.46 [-26, -0.28] -1.46 [-26, -0.28] -1.46 [-26, -0.28] -0.35 [-14, -0.21] -0.35 [-14, -0.59] -0.35 [-14, -0.59] -0.35 [-14, -0.28] -0.86 [-1.44, -0.28] -0.67 [-1.12, -0.21]	Std. Man Difference IV. Random 35% CI	Budy or Subprove 1.1.1 with rehabilities Boutier 2016 Korzhowa 2019 Korzłowa 2019 Korzłowa 2019 Korzłowa 2019 Korzłowa 2019 Korzłowa 2019 Korzłowa 2019 Korzłowa 2019 Korzych (C) Heterogenejky, Tau ⁺ Test for overali effect: Total (6%; C) Heterogenejky, Tau ⁺ Test for overali effect: Total (6%; C) Test for overali effect: Total (6%; C) Test for overali effect: Test for overali effect	$\begin{array}{rrrr} TMS \ group \\ Maan & SD & Tota \\ Maan & SD & Tota \\ -8.8 & 19.6 & 1.2 \\ -3.8 & 19.6 & 1.2 \\ -3.8 & 19.6 & 1.2 \\ -3.8 & 0.4 & 1.1 \\ -3.5 & 6.2 & 2 \\ -1.1 & 1.45 & 1.1 \\ -3.5 & 6.2 & 2 \\ -1.1 & 1.45 & 1.1 \\ -3.5 & 6.2 & 2 \\ -1.1 & 1.45 & 1.1 \\ -3.5 & 4.39 & (P & 0.0001 \\ -3.5 & 4.39 & (P & 0.0011 \\ -3.5 & -3.5 & -3.5 \\ -3.5 & -3.5 & -3.5 \\ -3.5 & -3.5 & -3.5 \\ -3.5 & -3.5 & -3.5 \\ -3.5 & -3.5 & -3.5 \\ -3.5 & -3.5 & -3.5 \\ -3.5 & -3.5 & -3.5 \\ -3.5 & -3.5 & -3.5 \\ -3.5 & -3.5 & -3.5 \\ -3.5 & -3.5 & -3.5 \\ -3.5 & -3.5 & -3.5 \\ -3.5 & -3.5 & -3.5 \\ -3.5 & -3.5 & -3.5 \\ -3.5 & -3.5 & -3.5 \\ -3.5 & -3.5 & -3.5 \\ -3.5 & -3.5 & -3.5 \\ -3$	sham gr 1 Mean Si 2 -0.2 0.4 2 -0.2 0.4 2 -0.2 0.4 2 -0.2 0.4 0 -0.4 0.4 -1.2 7. 0 0.16 0.8 5 (P = 0.50) -1.8 1.7 0 -0.6 1.8 2 0.02 1.6 0 -1.98 1.7 3 4 = 8 (P = 0.0 df = 1 (P = 0.2) df = 1 (P = 0.2)	Poing D Total Weig D Total Weig No D Total Weig No 3 8 10.7. S S 2 5 9.6 No S S 4 17 15.7 S	Std. Mean Difference. ht IV. Random. 35% CI. ht IV. IV. Random. 35% CI. ht IV. IV. Random. 35% CI. ht IV. Random. 35% CI.	Std. Mean Difference IV. Random. 95% CI	

Figure 4. Standardized mean difference in change in spasticity scores from baseline between the rTMS and control groups, stratified by (**A**) type of multiple sclerosis (MS), (**B**) type of intervention, (**C**) sex ratio, and (**D**) whether combined with conventional rehabilitation. CI: confidence interval; df: degrees of freedom; IV: inverse variance; SD: standard deviation; Std: standardized; rTMS: repetitive transcranial magnetic stimulation. See Table 1 for reference numbers.



Figure 5. Funnel plot for publication bias for primary outcome. SE: standard error; SMD: standardized mean difference.

improvement of modified Ashworth scale scores was reported (pooled MD: -0.91; 95%CI: -1.91 to 0.09; P=0.07) (34). Although this provided valuable information, the overall quantitative synthetic data were based on a whole range of MS patients. Results of an early doubleblind study by Nielsen et al. (24) pointed out that rTMS has beneficial effects against spasticity in patients with MS, which is inconsistent with this previously published metaanalysis. However, we found that the authors of the previous meta-analysis missed this important clinical study in the process of literature screening and data extraction for unknown reasons, which might bias the overall effect. We performed this study based on a notable assumption. Compared with previous systematic reviews, we focused exclusively on patients diagnosed with MSrelated spasticity, as these patients are most likely to reveal a direct benefit of rTMS on spasm-related outcomes. Moreover, additional subgroup analyses according to different characteristics for each trial helped identify potential moderators affecting the efficacy of rTMS.

Despite the short-term positive effect of rTMS (P=0.004), patients randomized to stimulation versus control showed no trend toward a spasticity reduction at the follow-up visit 2 weeks later (P=0.32). Due to the limited number of studies and inconsistent follow-up period, this result should be interpreted carefully, and more evidence is required for its confirmation. In addition, no significant advantage of rTMS over sham has been found for improving fatigue, in line with Chen et al. (26) meta-analysis. In stratified analyses for the outcome of spasticity, a beneficial effect was observed for HF-rTMS application for SP MS in trials with the proportion of females > 50% and in trials in which rTMS application was combined with rehabilitation training. It should be noted that no safety end-points are provided in our metaanalysis. Although Nielsen et al. (24) reported a case of irregular heartbeats 2 h after stimulation, no adverse

effects were reported in other trials included in our metaanalysis, suggesting that rTMS treatment was safe and acceptable for most patients.

The beneficial effects of rTMS are likely to be mediated through changes in cortical excitability at the site of stimulation and by trans-synaptic changes at distant sites. Researchers speculate that rTMS induces lasting inhibitory or stimulatory aftereffects on corticospinal motor output, which may be due to long-term depression-like and long-term potentiation-like mechanisms, beyond the shifting in network excitability, activation of feedback loops, and activity-dependent metaplasticity phenomena (34,35). In this case, previous synaptic activities influence the level of reactivity to subsequent stimuli. Therefore, a priming stimulation may change various synaptic properties thus altering the effects of a subsequent plasticity-inducing event.

Despite the presence of some differences in the physiological effects, both the HF-rTMS and the iTBS protocols have the ability to increase the excitability of the motor cortex. It has been theorized that iTBS more closely mimics the brain's natural neuronal firing patterns and produces more robust changes in cortical excitability. thereby providing a more optimized cortical environment than the conventional HF-rTMS protocol for improved performance of the task (36). However, our analysis showed that HF-rTMS is non-inferior to iTBS for the treatment of spasticity in patients with MS. We speculated that the observed non-inferior effectiveness may be related to the differences of cumulative effects between iTBS and HF-rTMS. Further research including neural mechanisms is warranted. There is an emerging view that RR MS and SP MS are part of a disease continuum with an indistinct boundary, in which disability progression may result from neurodegeneration that is not linked to inflammation (37). This theory may explain the nonsignificant subgroup difference based on MS type. However, the possibility of chance findings cannot be ruled out due to the small number of studies for different subgroups and the small sample sizes of the included studies. Exercise rehabilitation is thought to facilitate activity-dependent neuroplasticity involving spinal pattern generators or motor pathways in the brain (38), and has

References

- World Health Organization (WHO). Atlas: Country resources for neurological disorders. Programme for Neurological Diseases and Neuroscience, Geneva; 2004.
- Dobson R, Giovannoni G. Multiple sclerosis a review. Eur J Neurol 2019; 26: 27–40, doi: 10.1111/ene.13819.
- Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. *Lancet* 2018; 391: 1622–1636, doi: 10.1016/S0140-6736(18)30481-1.
- 4. Fattore G, Lang M, Pugliatti M. The Treatment experience, burden, and unmet needs (TRIBUNE) study - measuring

been shown to modulate brain integrity/volume and functional connectivity (39). Additionally, direct central anti-inflammatory and pro-myelinating effects of exercise have been demonstrated in demyelinating models (40).

Through our comprehensive search strategy, stringent inclusion/exclusion criteria, and pre-specified subgroup analyses, we believe that we offer a valid summary of the published literature on rTMS in MS-related spasticity. As with any systematic review, the inherent limitations apply also to the present meta-analysis: lack of rigorous methodology and variable use of outcome measures, differences in the duration and severity of the disease among trials, and lack of robust studies with low bias, appropriate sample sizes, and power to detect expected differences. In addition, the follow-up periods varied between trials with most being immediately after treatment or up to 2 weeks. Only one trial reported long-term followup of up to 12 weeks, but this was restricted only for evaluation of patient-reported symptoms using subjective questionnaires (21): thus, the long-term response of rTMS therapy on MS-related spasticity could not be assessed. Also, for the secondary outcomes and the baseline features of interest, the numbers of studies included in quantitative analyses were extremely small; therefore, the results may be unreliable and need to be further tested in prospective studies.

Conclusion

The result of this study suggested that real rTMS was superior to sham condition in reducing MS-related limb spasticity in the early post-intervention period. The effectiveness of rTMS on reducing spasticity at the short-term follow-up and fatigue was not significant. Taken together, our data supported recommendations to treat these patients with rTMS, but emphasized the need for large randomized trials before the result of this review can be generalized.

Supplementary Material

Click here to view [pdf].

the socioeconomic consequences of Multiple Sclerosis. *Mult Scler* 2012; 18: 5–6, doi: 10.1177/1352458512447 262.

- Patwardhan MB, Matchar DB, Samsa GP, McCrory DC, Williams RG, Li TT. Cost of multiple sclerosis by level of disability: a review of literature. *Mult Scler* 2005; 11: 232– 239, doi: 10.1191/1352458505ms1137oa.
- Barnes MP, Kent RM, Semlyen JK, McMullen KM. Spasticity in multiple sclerosis. *Neurorehabil Neural Repair* 2003; 17: 66–70, doi: 10.1177/0888439002250449.

- Kesselring J, Thompson AJ. Spasticity, ataxia and fatigue in multiple sclerosis. *Baillieres Clin Neurol* 1997; 6: 429–445.
- Hobart JC, Riazi A, Thompson AJ, Styles IM, Ingram W, Vickery PJ, et al. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). *Brain* 2006; 129: 224–234, doi: 10.1093/brain/ awh675.
- Amatya B, Khan F, La Mantia L, Demetrios M, Wade DT. Non pharmacological interventions for spasticity in multiple sclerosis. *Cochrane Database Syst Rev* 2013; CD009974, doi: 10.1002/14651858.CD009974.pub2.
- O'Dwyer NJ, Ada L. Reflex hyperexcitability and muscle contracture in relation to spastic hypertonia. *Curr Opin Neurol* 1996; 9: 451–455, doi: 10.1097/00019052-1996 12000-00010.
- Lindsay C, Kouzouna A, Simcox C, Pandyan AD. Pharmacological interventions other than botulinum toxin for spasticity after stroke. *Cochrane Database Syst Rev* 2016; 10: CD010362, doi: 10.1002/14651858.CD010362.pub2.
- Yelnik AP, Simon O, Bensmail D, Chaleat-Valayer E, Decq P, Dehail P, et al. Drug treatments for spasticity. *Ann Phys Rehabil Med* 2009; 52: 746–756, doi: 10.1016/j.rehab.2009. 09.005.
- Lazorthes Y, Sol JC, Sallerin B, Verdié JC. The surgical management of spasticity. *Eur J Neurol* 2002; 9: 35–41, doi: 10.1046/j.1468-1331.2002.0090s1035.x.
- Leocani L, Nuara A, Formenti A, Rossi P, Zangen A, Comola M, et al. Deep rTMS with H-Coil associated with rehabilitation enhances improvement of walking abilities in patients with progressive multiple sclerosis: randomized, controlled, double blind study (S49.007). *Neurology* 2012; 78: S49.007.
- Di Lazzaro V, Pilato F, Saturno E, Oliviero A, Dileone M, Mazzone P, et al. Theta-burst repetitive transcranial magnetic stimulation suppresses specific excitatory circuits in the human motor cortex. *J Physiol* 2005; 565: 945–950, doi: 10.1113/jphysiol.2005.087288.
- Huang YZ, Edwards MJ, Rounis E, Bhatia KP, Rothwell JC. Theta burst stimulation of the human motor cortex. *Neuron* 2005; 45: 201–206, doi: 10.1016/j.neuron.2004.12.033.
- Rossi S, Hallett M, Rossini PM, Pascual-Leone A. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. *Clin Neurophysiol* 2009; 120: 2008–2039, doi: 10.1016/j.clinph.2009.08.016.
- Boutière C, Rey C, Zaaraoui W, Le Troter A, Rico A, Crespy L, et al. Improvement of spasticity following intermittent theta burst stimulation in multiple sclerosis is associated with modulation of resting-state functional connectivity of the primary motor cortices. *Mult Scler* 2017; 23: 855–863, doi: 10.1177/1352458516661640.
- Centonze D, Koch G, Versace V, Mori F, Rossi S, Brusa L, et al. Repetitive transcranial magnetic stimulation of the motor cortex ameliorates spasticity in multiple sclerosis. *Neurology* 2007; 68: 1045–1050, doi: 10.1212/01.wnl.00002 57818.16952.62.
- Dieguez-Varela C, Lion-Vazquez S, Fraga-Bau A, Rodriguez-Acevedo B, Rodriguez-Sanchez L, Collazo-Dieguez M, et al. Intermittent theta-burst transcranial magnetic stimulation for the treatment of spasticity in patients with recurring multiple sclerosis: the results of a double-blind

randomised clinical trial [in Spanish]. *Rev Neurol* 2019; 69: 45–52, doi: 10.33588/rn.6902.2018275.

- Korzhova J, Bakulin I, Sinitsyn D, et al. High-frequency repetitive transcranial magnetic stimulation and intermittent theta-burst stimulation for spasticity management in secondary progressive multiple sclerosis. *Eur J Neurol.* 2019; 26(4): 680–e44, doi: 10.1111/ene.13877.
- Mori F, Codecà C, Kusayanagi H, Monteleone F, Boffa L, Rimano A, et al. Effects of intermittent theta burst stimulation on spasticity in patients with multiple sclerosis. *Eur J Neurol* 2010; 17: 295–300, doi: 10.1111/j.1468-1331.2009.02806.x.
- Mori F, Ljoka C, Magni E, Codecà C, Kusayanagi H, Monteleone F, et al. Transcranial magnetic stimulation primes the effects of exercise therapy in multiple sclerosis. *J Neurol* 2011; 258: 1281–1287, doi: 10.1007/s00415-011-5924-1.
- Nielsen JF, Sinkjaer T, Jakobsen J. Treatment of spasticity with repetitive magnetic stimulation; a double-blind placebocontrolled study. *Mult Scler* 1996; 2: 227–232, doi: 10.1177/ 135245859600200503.
- Şan AU, Yılmaz B, Kesikburun S. The effect of repetitive transcranial magnetic stimulation on spasticity in patients with multiple sclerosis. *J Clin Neurol* 2019; 15: 461–467, doi: 10.3988/jcn.2019.15.2.250.
- Chen X, Yin L, An Y, Yan H, Zhang T, Lu X, et al. Effects of repetitive transcranial magnetic stimulation in multiple sclerosis: a systematic review and meta-analysis. *Mult Scler Relat Disord* 2022; 59: 103564, doi: 10.1016/j.msard.2022. 103564.
- Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. *Ann Intern Med* 2009; 151: 264–269, W64, doi: 10.7326/0003-4819-151-4-200908 180-00135.
- Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. (2011). Available from: http://www.cochrane-hand book.org.
- Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003; 327: 557–560, doi: 10.1136/bmj.327.7414.557.
- Egger M, Smith GD, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. *BMJ*. 1997; 315: 629–634, doi: 10.1136/bmj.315.7109.629.
- Mullick AA, Musampa NK, Feldman AG, Levin MF. Stretch reflex spatial threshold measure discriminates between spasticity and rigidity. *Clin Neurophysiol* 2013; 124: 740– 751, doi: 10.1016/j.clinph.2012.10.008.
- Tardieu G, Tardieu C, Colbeau-Justin P, Bret MD. Effects of muscle length on an increased stretch reflex in children with cerebral palsy. *J Neurol Neurosurg Psychiatry* 1982; 45: 348–352, doi: 10.1136/jnnp.45.4.348.
- Kamper DG, Schmit BD, Rymer WZ. Effect of muscle biomechanics on the quantification of spasticity. *Ann Biomed Eng* 2001; 29: 1122–1134, doi: 10.1114/1.1424918.
- Kobayashi M, Pascual-Leone A. Transcranial magnetic stimulation in neurology. *Lancet Neurol* 2003; 2: 145–156, doi: 10.1016/S1474-4422(03)00321-1.
- Matsuzaki M, Honkura N, Ellis-Davies GCR, Kasai H. Structural basis of long-term potentiation in single dendritic

spines. *Nature* 2004; 429: 761–766, doi: 10.1038/nature02 617.

- Benali A, Trippe J, Weiler E, Mix A, Petrasch-Parwez E, Girzalsky W, et al. Theta-burst transcranial magnetic stimulation alters cortical inhibition. *J Neurosci* 2011; 31: 1193–1203, doi: 10.1523/JNEUROSCI.1379-10.2011.
- Lassmann H. pathogenic mechanisms associated with different clinical courses of multiple sclerosis. *Front Immunol* 2019; 9: 3116, doi: 10.3389/fimmu.2018.03116.
- Mandolesi G, Bullitta S, Fresegna D, De Vito F, Rizzo FR, Musella A, et al. Voluntary running wheel attenuates motor

deterioration and brain damage in cuprizone-induced demyelination. *Neurobiol Dis* 2019; 129: 102–117, doi: 10.1016/j.nbd.2019.05.010.

- 39. Baird JF, Sandroff BM, Motl RW. Therapies for mobility disability in persons with multiple sclerosis. *Expert Rev Neurother* 2018; 18: 493–502, doi: 10.1080/14737175.2018. 1478289.
- Prosperini L, Di Filippo M. Beyond clinical changes: rehabilitation-induced neuroplasticity in MS. *Mult Scler* 2019; 25: 1348–1362, doi: 10.1177/1352458519846 096.